Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan
This article was originally published in The Pink Sheet Daily
Executive Summary
After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.
You may also be interested in...
Genentech Moves To Dampen Avastin Use In Wet AMD By Limiting Sales To Compounding Pharmacists
As of Nov. 30, Avastin can no longer be purchased by compounding pharmacists from wholesale distributors, company announces in "Dear Retinal Community Member" letter.
Genentech Moves To Dampen Avastin Use In Wet AMD By Limiting Sales To Compounding Pharmacists
As of Nov. 30, Avastin can no longer be purchased by compounding pharmacists from wholesale distributors, company announces in "Dear Retinal Community Member" letter.
ESA Committee Review To Focus On Hemoglobin Target For Kidney Disease
FDA advisory panel will also be asked to discuss management of non-responders at increased risk for cardiovascular harm.